Shanghai Bocimed Pharmaceutical Co.,Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Shanghai Bocimed Pharmaceutical Co.,Ltd.

12 YRS

Shanghai, China

CNY 39.8 Million

19980 m²

100-500 people

Main Products: Relugolix / Carfilzomib / Ixazomib Citrate / Apalutamide / Avatrombopag / Fulvestrant / Lenvatinib Mesylate / Ruxolitinib Phosphate / Roxadustat / Brivaracetam

Shanghai, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

CRO

Total Employees

100-500 People

Plant Size

30 Acres

Production Experience

12+ Years

Registered Capital

CNY 39.8 Million

MAIN
PRODUCTS

1/3

Relugolix

CAS: 737789-87-6

Packing: 1 KG/BOTTLE

Lead Time: 14-30 days

Inquiry

1/3

Carfilzomib

CAS: 868540-17-4

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

1/3

Ixazomib Citrate

CAS: 1239908-20-3

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

ABOUT US

Shanghai Bocimed Pharmaceutical Co.,Ltd.

Shanghai Bocimed Pharmaceutical Co., Ltd. (Bocimed) was established in Shanghai Zhangjiang Pharma Valley in 2012. Having two internal R&D centers settled in Shanghai and Nanjing, and a subsidiary clinical company in Chengdu, Bocimed now established an efficient R&D team with about 200 staffs and possesses specialized R&D equipments worth more 40 million RMB. Our comprehensive R&D platform mainly focuses upon small molecule innovative drugs, modified innovative drugs, highly difficult pharmaceutical preparations, DMF&MAH and clinical research, committing to provide global pharmaceutical companies with extremely competitive drug and create international and frontier pharmaceutical R&D and innovative platform. Bocimed has more than 100 product development technologies, focusing on various therapeutic areas including oncology, cardiovascular science, immunology, neurological and mental health. With well-established internal intellectual property system,we have 16 authorized and 47 pending approval patents up to now.